MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Immunocore Holdings PLC ADR

Abierto

30.54 4.09

Resumen

Variación precio

24h

Actual

Mínimo

29.08

Máximo

30.87

Métricas clave

By Trading Economics

Ingresos

-33M

-24M

Ventas

3.8M

84M

BPA

-0.49

Margen de beneficios

-28.281

Empleados

493

EBITDA

-6.8M

-15M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+124.16% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-49M

1.5B

Apertura anterior

26.45

Cierre anterior

30.54

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

Immunocore Holdings PLC ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 abr 2025, 23:54 UTC

Acciones populares

Stocks to Watch: Alphabet, Intel, AppFolio

24 abr 2025, 23:51 UTC

Charlas de Mercado

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 abr 2025, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 abr 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 abr 2025, 23:37 UTC

Principales Noticias

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 abr 2025, 23:36 UTC

Principales Noticias

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 abr 2025, 23:13 UTC

Principales Noticias
Ganancias

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 abr 2025, 23:09 UTC

Principales Noticias

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 abr 2025, 23:02 UTC

Adquisiciones, fusiones, absorciones

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 abr 2025, 23:02 UTC

Adquisiciones, fusiones, absorciones

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 abr 2025, 22:51 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 abr 2025, 22:48 UTC

Principales Noticias

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 abr 2025, 22:47 UTC

Charlas de Mercado

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 abr 2025, 22:38 UTC

Charlas de Mercado
Ganancias

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 abr 2025, 22:24 UTC

Ganancias

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 abr 2025, 22:24 UTC

Ganancias

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 abr 2025, 22:24 UTC

Charlas de Mercado
Ganancias

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 abr 2025, 22:23 UTC

Ganancias

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 abr 2025, 22:11 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

24 abr 2025, 22:11 UTC

Charlas de Mercado
Ganancias

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 abr 2025, 22:09 UTC

Principales Noticias
Ganancias

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 abr 2025, 22:00 UTC

Charlas de Mercado
Ganancias

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 abr 2025, 21:39 UTC

Principales Noticias

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 abr 2025, 21:24 UTC

Principales Noticias
Ganancias

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 abr 2025, 21:24 UTC

Principales Noticias
Ganancias

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 abr 2025, 21:23 UTC

Principales Noticias
Ganancias

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 abr 2025, 21:04 UTC

Ganancias

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 abr 2025, 21:03 UTC

Ganancias

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 abr 2025, 21:03 UTC

Ganancias

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 abr 2025, 21:02 UTC

Ganancias

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Comparación entre iguales

Cambio de precio

Immunocore Holdings PLC ADR previsión

Precio Objetivo

By TipRanks

124.16% repunte

Estimación a 12 Meses

Media 66.8 USD  124.16%

Máximo 100 USD

Mínimo 33 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Immunocore Holdings PLC ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

9

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

29.85 / 30.85Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.